2025년 03월 09일 일요일
 
 
  현재위치 > 뉴스지닷컴 > Business

랜섬웨어부터 돼지도살까지... 노련해진 사기행각

 

정치

 

경제

 

사회

 

생활

 

문화

 

국제

 

과학기술

 

연예

 

스포츠

 

자동차

 

부동산

 

경영

 

영업

 

미디어

 

신상품

 

교육

 

학회

 

신간

 

공지사항

 

칼럼

 

캠페인
한살림 ‘우리는 한쌀림’ 쌀 소비 캠페인 시...
1000만원짜리 인공와우, 건강보험 지원 ‘평...
- - - - - - -
 

Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate

Collaboration continues to expand portfolio in women’s health to help address unmet needs
뉴스일자: 2022-07-29

JERSEY CITY, N.J.-- July 29, 2022 -- Organon (NYSE: OGN), a global women’s healthcare company, and Cirqle Biomedical today announced they have entered into a research collaboration and exclusive license agreement for a novel investigational non-hormonal, on-demand contraceptive candidate.

“As a leader in contraception, we believe it is critically important to bring forward new options for women, especially in the space of non-hormonal contraceptives, a category preferred by many with limited available options,” said Sandra Milligan, M.D., Organon’s head of Research and Development. “Organon is committed to driving innovation across women’s health and collaborating with companies like Cirqle Biomedical to support early science and bring forward new solutions that address the unmet needs of women.”

Encouraging preclinical research suggests that Cirqle has discovered a method that has the potential to create a temporary barrier to sperm transport by topically reinforcing the existing cervical mucus barrier.

“This collaboration is an important opportunity to advance our preclinical research exploring this asset’s first-in-class potential,” said Frederik Petursson Madsen, Cirqle Biomedical, CEO. “We are excited to join Organon to leverage Organon’s deep expertise in women’s and reproductive health to drive potential change for women who use contraception everywhere.”

Under the terms of the agreement, Cirqle will be responsible for conducting preclinical studies according to the mutually agreed research plan. Organon will obtain exclusive worldwide rights to develop and commercialize the asset. Cirqle is entitled to receive a $10 million upfront payment, potential milestone payments of up to $360 million and royalties based on net sales.

As stated on Organon’s first quarter conference call, to align with views expressed by the US Securities and Exchange Commission, beginning in 2022 Organon will no longer exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, from its non-GAAP results. Organon’s financial guidance does not assume an estimate for these expenses associated with business development not yet executed, and accordingly, the $10 million upfront payment was not included in the full year 2022 guidance Organon provided on May 5, 2022. Organon does not plan to update its guidance inter-quarter based solely on these items.



 전체뉴스목록으로

Esri Launches Content Store for ArcGIS to Provide Easier Access to On-Demand, GIS-Ready Imagery
SLB provides update on planned acquisition of ChampionX
Autel Energy Debuts Ultra-Fast MaxiCharger DH480 at EVCharge Live Thailand 2025
SEMPRE Partners with Radisys to Develop Resilient and Secure 5G Infrastructure
Turing Secures $14 Million to Scale AI-Powered Water Management Solutions
Andersen Global Strengthens Saudi Arabia Presence with Al-Sharif Law Firm
BROADMEDI and KHCA Sign Strategic MOU to Enhance Medical Tourism Services

 

Multiply Group Signs Landmark Investment with CVC and PAI Partners to ...
Corpay Cross-Border Named the Official FX Payments Supplier of the FIG
Large Jet Sales Signal Revived Market Confidence, Reveals Jetcraft’s ...
The Asia Group Welcomes The Honorable Dr. Kurt M. Campbell as Chairman...
Dolce & Gabbana’s $1M Glass Suit Fractionalization by Fermion launche...
LG Reveals Latest DUALCOOL AI Air Conditioner With Enhanced AI Technol...
Gradiant and GF Piping Systems Partner to Drive Innovation and Sustain...

 


공지사항
알리알 Allial 중문 표기 '阿利尔'
바이오이니 Bioini 중문 표기 必药研 必藥硏
엔코스모스 EnCosmos 중문 표기 以宙
뉴퍼스트 New1st 중문 표기 纽壹新(번체 紐壹新)
알리우브 Alliuv 중문 표기 '阿联备'
오스프롬 Ausfrom 중문 표기 奥斯福牧
에너프롬 Enerfrom 중문 표기 额能福牧(額能福牧)
베네프롬 베네인투 중문 표기 宝乃福牧 宝乃因托(寶乃福牧 寶...
알프롬 Alfrom 중문 표기 阿尔福牧 阿爾福牧
뉴스지 한자 표기에 대만식 음차 표기 '纽斯集 니우시지' 병기
뉴스그룹 정보 미디어 부문 상표등록
알프롬 계열 상표, 상표등록 완료

 

회사소개 | 인재채용 | 이용약관 | 개인정보취급방침 | 청소년보호정책 | 책임한계와 법적고지 | 이메일주소무단수집거부 | 고객센터

기사제보 이메일 news@newsji.com, 전화 050 2222 0002, 팩스 050 2222 0111, 주소 : 서울 구로구 가마산로 27길 60 1-37호

인터넷뉴스서비스사업등록 : 서울 자00447, 등록일자 : 2013.12.23., 뉴스배열 및 청소년보호의 책임 : 대표 CEO

Copyright ⓒ All rights reserved..